PharmaFrontiers Adds Three Members to Its Scientific Advisory Board.

THE WOODLANDS, Texas -- PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, announced today that it has appointed three new members to its scientific advisory board (SAB). The new members are Norman Barton, M.D., Ph.D., executive vice president and chief medical officer of CepTor Corporation; Daniel R. Marshak, Ph.D., senior vice president -- research and development, and chief technology officer for Cambrex; and Shelly Heimfeld, Ph.D., director of the Stem Cell Program at Fred Hutchinson Cancer Research Center in Seattle, Washington.

These new members join Eliezer Huberman, Ph.D. (SAB Chairman), the director of Biological & Biotechnological Research at the Argonne National Laboratory since 1981 and a noted authority in the area of adult pluripotent stem cell technology; and Dr. Jingwu Zhang, professor of Neurology and Immunology at Baylor College of Medicine and Scientific Director of the Baylor-Methodist Multiple Sclerosis Center in Houston since 1996.

"With these five distinguished scientists now serving on our SAB, we are in a much stronger position to move our therapies forward along the research and commercialization pathways as we stand to benefit from the advice borne of their collective years of experience," said David B. McWilliams, president and chief executive officer of PharmaFrontiers.

Dr. Barton, who was formally trained in biological chemistry and internal medicine and is a certified specialist in neurology, has had a distinguished career in investigative medicine and in the development of novel therapeutic agents in both the academic and commercial sectors. His many accomplishments include the development of an enzyme replacement therapy for a severely debilitating lipid storage disorder known as Gaucher disease, for which he received both the Outstanding and Meritorious Service Medals of the United States Public Health Service.

Prior to joining CepTor, Dr. Barton served as executive vice president and chief medical officer at Osiris Therapeutics (2002-2004), Biotechnology General Corp (1996-2002), and also served as a physician-scientist and Chief of the Clinical Investigations Section with the Neurological Institute at the National Institutes of Health (1985-1996).

Dr. Barton received his M.D. and Ph.D. degrees from Pennsylvania State University, and he completed his residency in Internal Medicine at Albany Medical College Hospital and his residency in Neurology at Cornell University New York Hospital.

Dr. Marshak is a renowned molecular biologist who has served on several NIH Study Sections, the Medical and Scientific Advisory Board of the Dystonia Medical Research Foundation, and the Editorial Board of the Journal of Biological Chemistry. He is also an Adjunct Associate Professor of Oncology and of Molecular Biology & Genetics at the Johns Hopkins University School of Medicine.

Prior to joining Cambrex in 2000, Dr. Marshak held various Research and Development positions with Osiris Therapeutics and was a former senior staff investigator at the Cold Spring Harbor Laboratory (1986-1994). Daniel Marshak received his B.A. from Harvard University in biochemistry and molecular biology and his Ph.D. from Rockefeller University. He did postdoctoral research in pharmacology at Vanderbilt University School of Medicine and at the National Institutes of Health.

Dr. Heimfeld is an Associate Faculty Member and serves as the Laboratory Director of the Cellular Therapy and cGMP Cell Processing Facilities at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He has a broad range of research interests, with a particular focus on the development of improved therapeutic strategies using various human stem cell populations. His long-term goals for this area are to identify better markers for the characterization of stem and progenitor cells, to improve isolation technologies for enriching these types of cells, and to develop ex-vivo manipulation strategies that can enhance the therapeutic potential of these cells. Dr. Heimfeld has also been involved in the development of T-cell based immunotherapy for various diseases. Dr. Heimfeld currently serves as President-elect for ISCT (International Society of Cellular Therapy). He is also on the Board of Directors for FACT (Foundation for the Accreditation of Cellular Therapy) and is a leading authority in GLP, GTP and GMP regulations, working with the FDA to facilitate exchange of ideas in the rapidly evolving area of Cell Therapy. Dr. Heimfeld received his Ph.D. in Cell Differentiation from the University of California, Irvine.

About PharmaFrontiers Corporation

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions and Multiple Sclerosis. The company holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. PharmaFrontiers also owns patented and proprietary individualized cell therapies that are in FDA Phase I/II human dose ranging clinical trials to evaluate their safety and effectiveness in treating MS.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.